scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00066-014-0620-6 |
P698 | PubMed publication ID | 24658605 |
P50 | author | George Pentheroudakis | Q90394491 |
Ioannis Efstratiou | Q114420979 | ||
Georgia Karayannopoulou | Q116791801 | ||
Irene Papaspirou | Q116791807 | ||
Sofia Lambaki | Q116791809 | ||
Mattheos Bobos | Q41163950 | ||
George Fountzilas | Q56432880 | ||
Anastasia G Eleftheraki | Q59680297 | ||
P2093 | author name string | Nikolaos Zamboglou | |
Georgios Lazaridis | |||
P2860 | cites work | Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer | Q77673978 |
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Q80358653 | ||
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer | Q27824857 | ||
Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer | Q33303529 | ||
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. | Q33377581 | ||
Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer | Q36081088 | ||
Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas | Q36305404 | ||
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. | Q36753651 | ||
Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma | Q37243478 | ||
DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer | Q37301839 | ||
Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function | Q37676970 | ||
Biomarkers and surrogate end points--the challenge of statistical validation | Q37724573 | ||
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. | Q37877173 | ||
mTOR signaling pathway and mTOR inhibitors in cancer therapy | Q38004213 | ||
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up | Q43695203 | ||
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer | Q43700699 | ||
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers | Q45121992 | ||
DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast | Q45890164 | ||
REporting recommendations for tumor MARKer prognostic studies (REMARK). | Q46099462 | ||
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 | ||
The Akt pathway in human breast cancer: a tissue-array-based analysis | Q46845226 | ||
The association between Akt activation and resistance to hormone therapy in metastatic breast cancer | Q46932769 | ||
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. | Q53365961 | ||
Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. | Q53441914 | ||
Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma. | Q54450580 | ||
[Molecular signaling pathways. Mechanisms and clinical use]. | Q54489564 | ||
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial | Q57904482 | ||
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration | Q59822429 | ||
Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases | Q70763612 | ||
P433 | issue | 7 | |
P304 | page(s) | 636-8, 640-5 | |
P577 | publication date | 2014-07-01 | |
P1433 | published in | Strahlentherapie und Onkologie | Q15724604 |
P1476 | title | Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer | |
P478 | volume | 190 |
Q90409992 | Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer |
Q92972106 | Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab |
Q57786864 | Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab |
Q64083584 | Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway |
Q41899812 | High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function |
Q36668028 | Hsa-miR-375 is a predictor of local control in early stage breast cancer |
Q33762003 | Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis |
Q36907273 | MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer |
Q34294000 | Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study |
Q36257635 | P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis |
Q28081992 | PI3K mutations in breast cancer: prognostic and therapeutic implications |
Q64117379 | Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome |
Q35801713 | Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study |
Q38264125 | mTOR pathway: A current, up-to-date mini-review (Review). |
Search more.